By high-throughput i-CR drug screening, they discovered that inhibition of the EGFR and MEK or CDK4/6 pathways exerted a synergistic inhibitory effect against colorectal cancer and supersynergistic effects when EGFR, MEK, and CDK4/6 inhibitors were used simultaneously. The gene discussed is MAP2K7; the disease is colorectal cancer.